pre-seed
Stage
1
Investors
About
Bonsai Biotherapeutics develops protein-based therapeutics aimed at restoring immune tolerance to self-proteins in autoimmune diseases such as myasthenia gravis and ANCA-associated vasculitis. Its leading candidate, TOL2 for myasthenia gravis, is planned to enter placebo-controlled clinical trials in 2026.
Explore Bonsai Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.